Matrix effect on serum uric acid determination

doi:10.3969/j.issn.1673-8640.2016.08.001

Abstract

Abstract:

Objective To evaluate the matrix effect of 21 samples （sera and processed materials） on 13 routine determination systems in serum uric acid determination. Methods Determinations were performed according to the health industry standard WS/T356-2011. Isotope dilution liquid chromatography tandem mass spectrometry （ID-LC/MS/MS）was used as comparison method,and 13 kinds of uric acid kits（enzymic assay） were chosen as evaluation method with HITACHI 7180 analyzer. The 21 samples included 4 calibrators,5 kinds of external quality assessment（EQA） samples,6 kinds of quality control materials,3 processed materials （1 kind of spine serum and 2 kinds of liquid solutions）,1 kind of standard reference material（SRM） 909c from the National Institute of Standards and Technology （NIST）and 2 kinds of the External Quality Assessment Scheme for Reference Laboratories in Laboratory Medicine （RELA）samples from the International Federation of Clinical Chemistry and Laboratory Medicine（IFCC）. A total of 40 fresh frozen sera and the 21 samples were analyzed by comparison method and evaluation method. The results obtained by the 2 methods were analyzed by linear regression analysis. Two-tailed 95% confidence intervals for Y predictive value were computed,and the matrix effect of sera and processed materials was evaluated. Results A total of 5 kinds of evaluation samples （2 EQA samples,1 SRM 909c and 2 RELA samples）from fresh or lyophilized sera showed no matrix effect in all routine methods. Two calibrators （Landau and Dirui） showed matrix effect in 1 routine method. Of 5 EQA samples,except for fresh sera used for trueness verification,other lyophilized sera showed matrix effect in most routine methods. The 4 of 6 quality control materials showed no matrix effect,and 2 quality control materials with high values showed negative matrix effect. Conclusions Fresh serum is a reliable sample and could be used in SRM and quality control material preparation and EQA. Some calibrators could introduce calibration bias due to matrix effect on non-matching routine methods. Thus,matrix effect evaluation and methodological verification are proposed prior to using non-matching calibrators.

Key words: Uric acid, Matrix effect, Enzymic assay, Isotope dilution, Liquid chromatography, Tandem mass spectrometry

CLC Number:

R446.1

ZHANG Jiangtao, ZENG Jie, MA Rong, ZHAO Haijian, ZHOU Weiyan, ZHANG Tianjiao, YAN Ying, HU Cuihua, WANG Jing, WANG Donghuan, ZHANG Chuanbao. Matrix effect on serum uric acid determination[J]. Laboratory Medicine, 2016, 31(8): 635-639.

样本	常规检测系统
样本	1	2	3	4	5	6	7	8	9	10	11	12	13
校准品1	-	N	N	-	N	N	N	-	-	N	N	N	N
校准品2	N	N	N	-	N	N	N	N	N	N	N	N	N
校准品3	N	N	N	N	N	N	N	N	N	N	N	N	-
校准品4	N	N	-	-	-	-	N	-	-	-	N	-	-
EQA1	+	+	+	N	N	+	+	+	N	+	N	+	+
EQA2	N	-	-	-	N	N	N	-	-	N	N	-	-
EQA3	-	-	-	-	-	-	-	-	-	N	-	-	-
EQA4	N	N	N	N	N	N	N	N	N	N	N	N	-
EQA5	-	N	N	-	N	-	-	N	N	N	N	N	-
质控品1	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品2	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品3	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品4	N	N	-	N	N	-	N	-	N	N	N	N	N
质控品5	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品6	N	-	-	-	-	-	-	N	-	N	-	-	-
制备物1	+	N	N	N	N	N	N	N	N	N	N	N	N
制备物2	N	N	N	N	N	N	N	N	N	N	N	N	N
制备物3	+	N	+	+	+	+	N	+	+	+	+	+	+
SRM 909c	N	N	N	N	N	N	N	N	N	N	N	N	N
RELA-A	N	N	N	N	N	N	N	N	N	N	N	N	N
RELA-B	N	N	N	N	N	N	N	N	N	N	N	N	N

样本	常规检测系统
样本	1	2	3	4	5	6	7	8	9	10	11	12	13
校准品1	-	N	N	-	N	N	N	-	-	N	N	N	N
校准品2	N	N	N	-	N	N	N	N	N	N	N	N	N
校准品3	N	N	N	N	N	N	N	N	N	N	N	N	-
校准品4	N	N	-	-	-	-	N	-	-	-	N	-	-
EQA1	+	+	+	N	N	+	+	+	N	+	N	+	+
EQA2	N	-	-	-	N	N	N	-	-	N	N	-	-
EQA3	-	-	-	-	-	-	-	-	-	N	-	-	-
EQA4	N	N	N	N	N	N	N	N	N	N	N	N	-
EQA5	-	N	N	-	N	-	-	N	N	N	N	N	-
质控品1	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品2	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品3	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品4	N	N	-	N	N	-	N	-	N	N	N	N	N
质控品5	N	N	N	N	N	N	N	N	N	N	N	N	N
质控品6	N	-	-	-	-	-	-	N	-	N	-	-	-
制备物1	+	N	N	N	N	N	N	N	N	N	N	N	N
制备物2	N	N	N	N	N	N	N	N	N	N	N	N	N
制备物3	+	N	+	+	+	+	N	+	+	+	+	+	+
SRM 909c	N	N	N	N	N	N	N	N	N	N	N	N	N
RELA-A	N	N	N	N	N	N	N	N	N	N	N	N	N
RELA-B	N	N	N	N	N	N	N	N	N	N	N	N	N

样本	靶值（μmol/L）	常规检测系统
样本	靶值（μmol/L）	1	2	3	4	5	6	7	8	9	10	11	12	13
校准品1	380.0	-5.0	-6.5	-1.9	-7.5	-1.7	-0.8	-4.1	-1.6	-5.1	-2.9	-6.2	-4.6	-11.1
校准品2	376.0	-3.5	-5.9	-0.8	-6.1	-1.0	0.3	-3.2	-0.8	-4.4	-2.1	-5.9	-4.4	-11.0
校准品3	376.6	-2.0	-6.2	0.7	-5.4	-0.8	0.8	1.1	0.4	-3.4	-1.0	-6.3	-3.6	-16.3
校准品4	366.2	-1.3	-5.6	-7.2	-13.8	-9.0	-1.6	-2.8	-3.2	-11.3	-4.6	-9.4	-9.0	-14.2
EQA1	127.4	24.7	13.8	18.4	6.6	21.6	27.3	23.4	25.6	11.9	24.2	17.9	19.7	8.5
EQA2	330.2	-3.8	-7.9	-4.0	-10.6	-4.8	-1.2	-4.8	-2.3	-9.2	-3.7	-7.4	-7.2	-13.4
EQA3	567.0	-3.6	-5.5	-4.0	-12.6	-6.4	-0.5	-4.0	-2.5	-11.0	-3.9	-7.1	-10.6	-14.0
EQA4	341.5	-1.8	-3.2	-0.5	-4.3	-1.5	1.5	-1.7	0.9	-1.5	-0.4	-5.8	-3.0	-8.3
EQA5	678.1	-2.0	-4.5	0.0	-4.4	-0.1	0.7	-2.2	0.3	-1.9	-1.0	-6.1	-2.1	-9.8
质控品1	349.6	-3.7	-5.5	-1.3	-6.0	-1.0	0.4	-3.2	-0.4	-4.9	-1.8	-6.1	-3.7	-11.3
质控品2	559.8	-2.2	-2.8	-0.4	-3.7	-1.4	1.7	0.4	0.1	-2.3	-1.3	-4.8	-1.9	-9.3
质控品3	305.5	-3.5	-4.5	-1.2	-3.8	1.5	0.2	-2.3	-0.8	-3.0	-2.2	-5.3	-0.1	-9.5
质控品4	649.7	-1.9	-4.0	-0.8	-3.8	-1.2	0.6	-0.9	-1.0	-2.3	-2.3	-5.2	-2.3	-9.1
质控品5	101.4	1.7	-8.3	-0.7	-5.0	12.7	-0.8	7.7	-0.1	1.3	-1.4	3.2	7.3	-15.8
质控品6	923.0	1.3	-8.4	-0.4	-6.3	-4.4	-0.5	-21.9	2.0	-2.1	0.6	-4.8	-8.3	-49.0
制备物1	30.6	100.5	-13.7	-7.6	-19.0	5.9	3.3	38.3	9.7	-19.9	8.4	-21.5	5.0	-35.0
制备物2	261.0	1.2	-2.8	0.9	0.5	6.9	4.1	2.0	2.6	1.2	1.3	0.1	5.7	-6.6
制备物3	399.3	10.5	1.3	10.2	10.8	13.7	9.2	5.7	10.0	10.6	8.7	7.8	13.7	-1.2
SRM 909c	278.4	-0.5	-3.6	2.5	0.9	4.4	0.5	-0.3	0.0	-1.8	-1.4	-2.4	1.4	-5.4
RELA-A	232.1	0.2	-4.5	-0.1	-2.9	3.6	1.1	0.9	-0.3	-2.0	-1.6	-4.0	2.2	-7.8
RELA-B	456.5	-0.1	-2.6	0.7	-2.4	1.1	2.1	1.6	0.6	-0.3	-0.8	-4.2	1.2	-7.3

样本	靶值（μmol/L）	常规检测系统
样本	靶值（μmol/L）	1	2	3	4	5	6	7	8	9	10	11	12	13
校准品1	380.0	-5.0	-6.5	-1.9	-7.5	-1.7	-0.8	-4.1	-1.6	-5.1	-2.9	-6.2	-4.6	-11.1
校准品2	376.0	-3.5	-5.9	-0.8	-6.1	-1.0	0.3	-3.2	-0.8	-4.4	-2.1	-5.9	-4.4	-11.0
校准品3	376.6	-2.0	-6.2	0.7	-5.4	-0.8	0.8	1.1	0.4	-3.4	-1.0	-6.3	-3.6	-16.3
校准品4	366.2	-1.3	-5.6	-7.2	-13.8	-9.0	-1.6	-2.8	-3.2	-11.3	-4.6	-9.4	-9.0	-14.2
EQA1	127.4	24.7	13.8	18.4	6.6	21.6	27.3	23.4	25.6	11.9	24.2	17.9	19.7	8.5
EQA2	330.2	-3.8	-7.9	-4.0	-10.6	-4.8	-1.2	-4.8	-2.3	-9.2	-3.7	-7.4	-7.2	-13.4
EQA3	567.0	-3.6	-5.5	-4.0	-12.6	-6.4	-0.5	-4.0	-2.5	-11.0	-3.9	-7.1	-10.6	-14.0
EQA4	341.5	-1.8	-3.2	-0.5	-4.3	-1.5	1.5	-1.7	0.9	-1.5	-0.4	-5.8	-3.0	-8.3
EQA5	678.1	-2.0	-4.5	0.0	-4.4	-0.1	0.7	-2.2	0.3	-1.9	-1.0	-6.1	-2.1	-9.8
质控品1	349.6	-3.7	-5.5	-1.3	-6.0	-1.0	0.4	-3.2	-0.4	-4.9	-1.8	-6.1	-3.7	-11.3
质控品2	559.8	-2.2	-2.8	-0.4	-3.7	-1.4	1.7	0.4	0.1	-2.3	-1.3	-4.8	-1.9	-9.3
质控品3	305.5	-3.5	-4.5	-1.2	-3.8	1.5	0.2	-2.3	-0.8	-3.0	-2.2	-5.3	-0.1	-9.5
质控品4	649.7	-1.9	-4.0	-0.8	-3.8	-1.2	0.6	-0.9	-1.0	-2.3	-2.3	-5.2	-2.3	-9.1
质控品5	101.4	1.7	-8.3	-0.7	-5.0	12.7	-0.8	7.7	-0.1	1.3	-1.4	3.2	7.3	-15.8
质控品6	923.0	1.3	-8.4	-0.4	-6.3	-4.4	-0.5	-21.9	2.0	-2.1	0.6	-4.8	-8.3	-49.0
制备物1	30.6	100.5	-13.7	-7.6	-19.0	5.9	3.3	38.3	9.7	-19.9	8.4	-21.5	5.0	-35.0
制备物2	261.0	1.2	-2.8	0.9	0.5	6.9	4.1	2.0	2.6	1.2	1.3	0.1	5.7	-6.6
制备物3	399.3	10.5	1.3	10.2	10.8	13.7	9.2	5.7	10.0	10.6	8.7	7.8	13.7	-1.2
SRM 909c	278.4	-0.5	-3.6	2.5	0.9	4.4	0.5	-0.3	0.0	-1.8	-1.4	-2.4	1.4	-5.4
RELA-A	232.1	0.2	-4.5	-0.1	-2.9	3.6	1.1	0.9	-0.3	-2.0	-1.6	-4.0	2.2	-7.8
RELA-B	456.5	-0.1	-2.6	0.7	-2.4	1.1	2.1	1.6	0.6	-0.3	-0.8	-4.2	1.2	-7.3

[1]	张传宝,闫颖,周伟燕,等. WS-T356-2011 基质效应与互通性评估指南[S]. 北京:中国标准出版社,2011.
[2]	张传宝,张江涛,张天娇,等. 同位素稀释液相色谱串联质谱法测定人血清尿酸[J]. 检验医学,2009,24(12):878-882.
[3]	赵海舰,周伟燕,张传宝,等. 血清总胆固醇测定的基质效应研究[J]. 现代检验医学杂志,2009,24(3):5-9.
[4]	周伟燕,赵海舰,张江涛,等. 血清总甘油测定基质效应的研究[J]. 中华检验医学杂志,2008,31(5):568-573.
[5]	赵海舰,张天娇,张传宝,等. 血清尿素测定的基质效应研究[J]. 中华检验医学杂志,2008,31(3):270-275.
[6]	张传宝,陈忠余,马嵘,等. 血清肌酐测定的基质效应研究[J]. 中华检验医学杂志,2009,32(5):515-520.

Matrix effect on serum uric acid determination

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 6

Related Articles 15

Recommended Articles

Metrics

[1]	LIN Jing, LI Quanle, YU Ting, WANG Huimin, SHEN Min, TU Minmin, CHEN Chuanding, PAN Jingjue, MA Jingxia. Establishment and performance evaluation of candidate reference measurement procedures for serum oxcarbazepine and 10-hydroxy carbamazepine [J]. Laboratory Medicine, 2025, 40(11): 1082-1090.
[2]	WANG Mengru, ZHOU Lin, XING Xiqian, CUI Qianqian. Predictive value of preoperative NLR combined with serum UA and PGE2 levels in elderly patients with hip fractures for postoperative delirium [J]. Laboratory Medicine, 2025, 40(10): 987-991.
[3]	FANG Huiling, JU Yi, OU Yuanzhu, ZHU Yuqing, LI Qing, JIN Zhonggan, ZHAO Xiaojun, FAN Xiaoyu, YU Keying. Current status of liquid chromatography-tandem mass spectrometry in clinical laboratories in Shanghai [J]. Laboratory Medicine, 2024, 39(9): 853-858.
[4]	WANG Xiaomei, LUO Chao, TIE Yang, HE Yong, YANG Xikui, LIU Yalin, SUN Yue, WANG Fugang, HE He. Application of random urine uric acid/creatinine in classification of hyperuricemia patients in Karamay [J]. Laboratory Medicine, 2024, 39(9): 859-864.
[5]	LIN Jing, PAN Qingqing, SHEN Min, XIE Yangmin, JIN Zhonggan, PAN Jingjue, LIU Jiajuan. Establishment and performance evaluation of candidate reference measurement procedures for serum voriconazole [J]. Laboratory Medicine, 2024, 39(7): 661-667.
[6]	ZHOU Fangfang, GU Xuemei, WANG Wei, LIN Ming, WANG Lei. Establishment and application of main components of Huang-Lian-Jie-Du decoction based on high performance liquid chromatography [J]. Laboratory Medicine, 2024, 39(5): 468-473.
[7]	ZHOU Ruiling, ZHANG Xinyu, REN Xiaoling, ZHANG Wen, FAN Changzheng, ZHANG Qiong. Relationship between uric acid/creatinine ratio and neutrophil/lymphocyte ratio and hypoxemia in patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Laboratory Medicine, 2024, 39(5): 474-479.
[8]	SONG Beiling, WU Jiong, HU Jiahua, WANG Yufei. Influence of common hemoglobin variants on different glycated hemoglobin determination systems [J]. Laboratory Medicine, 2024, 39(12): 1219-1223.
[9]	LI Xijiu, ZHOU Jianwei, ZHANG Qin, LONG Yunlin, WU Yingsong. Establishment and performance evaluation of UPLC-MS/MS for 6 markers in dried blood spots [J]. Laboratory Medicine, 2023, 38(5): 446-453.
[10]	XU Weixin, CHEN Qing, DU Wenyong, GAO Yan. Plasma metabolic markers in patients with insomnia disorder [J]. Laboratory Medicine, 2023, 38(5): 454-459.
[11]	WU Jie, LI Zenghe, CHEN Baorong, KONG Xujing. Establishment of traceable steroid hormone standard curve for dried blood spot samples [J]. Laboratory Medicine, 2023, 38(5): 489-493.
[12]	Expert Group on the Consensus on Androgen Testing in Polycystic Ovary Syndrome China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee. Consensus on androgen testing in polycystic ovary syndrome [J]. Laboratory Medicine, 2023, 38(3): 203-208.
[13]	YANG Xiaodong, LI Quanle, PAN Qingqing, ZHOU Jing, XIE Yangmin, ZOU Jihua, SHEN Min, ZHANG Man. Establishment and performance evaluation of candidate reference measurement procedure for the determination of immunosuppressive drugs in human whole blood by ID-LC-MS/MS [J]. Laboratory Medicine, 2023, 38(3): 215-222.
[14]	WANG Yajie, ZU Bailing, GAN Chenxin, WU Jiaoxiang, SHU Jie, HANG Chen, CHEN Minghui, LIN Fujun, HU Zhigang, HUANG Biao, SHENG Huiming. Identification of plasma differential peptids in PLA2R1-related membranous nephropathy patients [J]. Laboratory Medicine, 2023, 38(3): 223-229.
[15]	TANG Ningbo, LIU Guancai, LIU Xiaoyu, YANG Fengfan, GONG Zhimei, SUN Keqi. Establishment and evaluation for the determination of serum digitoxin as a candidate reference method [J]. Laboratory Medicine, 2022, 37(5): 456-462.